标签归档：骨髓瘤

CCF642

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CCF642  纯度: ≥98.0%

CCF642 是一种有效的蛋白质二硫键异构酶 (PDI) 抑制剂，IC50 为 2.9 μM。CCF642 在多发性骨髓瘤细胞中引起急性内质网 (ER) 应激，并伴随凋亡诱导的钙释放。CCF642 具有广泛的抗多发性骨髓瘤活性。

CCF642

CCF642 Chemical Structure

CAS No. : 346640-08-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥749 In-stock
2 mg ￥500 In-stock
5 mg ￥900 In-stock
10 mg ￥1250 In-stock
25 mg ￥2500 In-stock
50 mg ￥4500 In-stock
100 mg ￥6500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CCF642 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library

生物活性

CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity[1].

IC50 & Target

IC50: 2.9 μM (PDI)[1]
体外研究
(In Vitro)

CCF642 (3 μM; 0.5-6 hours) increases PERK dimerization by phosphorylation and IRE1-α oligomerization within 30 minutes in KMS-12-PE confirming accumulation of misfolded ER proteins[1].
CCF642, a bone marrow-sparing compound, exhibits a submicromolar IC50 in 10 of 10 multiple myeloma cell lines (MM1.S, MM1.R, KMS-12-PE, KMS-12-BM, NCI-H929, U266, RPMI 8226, JJN-3, HRMM.09-luc, 5TGM1-luc)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MM1.S cells
Concentration: 3 μM
Incubation Time: 0.5, 1, 2, 4, 6 hours
Result: Increased PERK dimerization by phosphorylation and IRE1-α oligomerization within 30 minutes in KMS-12-PE confirming accumulation of misfolded ER proteins.

体内研究
(In Vivo)

CCF642 (10 mg/kg; i.p.; three times a week; for 24 days) significantly prolongs life of 5TGM1-luc-bearing mice and suppresses 5TGM1-luc growth as determined by life imaging[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/KaLwRij mice of 6 to 8 weeks of age with 5TGM1-luc[1]
Dosage: 10 mg/kg
Administration: i.p.; three times a week; for 24 days
Result: Significantly prolonged life of 5TGM1-luc–bearing mice and suppressed 5TGM1-luc growth as determined by life imaging.

分子量

378.45

Formula

C15H10N2O4S3
CAS 号

346640-08-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 30 mg/mL (79.27 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6424 mL 13.2118 mL 26.4236 mL
5 mM 0.5285 mL 2.6424 mL 5.2847 mL
10 mM 0.2642 mL 1.3212 mL 2.6424 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 0.62 mg/mL (1.64 mM); Suspended solution; Need ultrasonic

    此方案可获得 0.62 mg/mL (1.64 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 6.2 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Vatolin S et al. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Res. 2016 Jun 1;76(11):3340-50.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Elotuzumab(Synonyms: Empliciti; HuLuc 63; PDL 063; BMS 901608)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Elotuzumab (Synonyms: Empliciti; HuLuc 63; PDL 063; BMS 901608)

Elotuzumab 是一种针对 SLAMF7 受体的单克隆抗体。当作为复发或难治性多发性骨髓瘤 (RRMM) 的单一药物给予时，Elotuzumab 没有显着的抗骨髓瘤活性。与其他抗骨髓瘤药物联合使用时，Elotuzumab 可改善反应和结果。

Elotuzumab(Synonyms: Empliciti; HuLuc 63; PDL 063; BMS 901608)

Elotuzumab Chemical Structure

CAS No. : 915296-00-3

规格 价格 是否有货
1 mg ￥2800 询问价格 & 货期
5 mg ￥8500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents[1].

CAS 号

915296-00-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务